217 related articles for article (PubMed ID: 24828813)
1. Differential effects of CSF-1R D802V and KIT D816V homologous mutations on receptor tertiary structure and allosteric communication.
Da Silva Figueiredo Celestino Gomes P; Panel N; Laine E; Pascutti PG; Solary E; Tchertanov L
PLoS One; 2014; 9(5):e97519. PubMed ID: 24828813
[TBL] [Abstract][Full Text] [Related]
2. Insight on Mutation-Induced Resistance from Molecular Dynamics Simulations of the Native and Mutated CSF-1R and KIT.
Da Silva Figueiredo Celestino Gomes P; Chauvot De Beauchêne I; Panel N; Lopez S; De Sepulveda P; Geraldo Pascutti P; Solary E; Tchertanov L
PLoS One; 2016; 11(7):e0160165. PubMed ID: 27467080
[TBL] [Abstract][Full Text] [Related]
3. Mutation D816V alters the internal structure and dynamics of c-KIT receptor cytoplasmic region: implications for dimerization and activation mechanisms.
Laine E; Chauvot de Beauchêne I; Perahia D; Auclair C; Tchertanov L
PLoS Comput Biol; 2011 Jun; 7(6):e1002068. PubMed ID: 21698178
[TBL] [Abstract][Full Text] [Related]
4. Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant.
Frost MJ; Ferrao PT; Hughes TP; Ashman LK
Mol Cancer Ther; 2002 Oct; 1(12):1115-24. PubMed ID: 12481435
[TBL] [Abstract][Full Text] [Related]
5. A juxtamembrane tyrosine in the colony stimulating factor-1 receptor regulates ligand-induced Src association, receptor kinase function, and down-regulation.
Rohde CM; Schrum J; Lee AW
J Biol Chem; 2004 Oct; 279(42):43448-61. PubMed ID: 15297464
[TBL] [Abstract][Full Text] [Related]
6. Allosteric communication across the native and mutated KIT receptor tyrosine kinase.
Laine E; Auclair C; Tchertanov L
PLoS Comput Biol; 2012; 8(8):e1002661. PubMed ID: 22927810
[TBL] [Abstract][Full Text] [Related]
7. Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.
Growney JD; Clark JJ; Adelsperger J; Stone R; Fabbro D; Griffin JD; Gilliland DG
Blood; 2005 Jul; 106(2):721-4. PubMed ID: 15790786
[TBL] [Abstract][Full Text] [Related]
8. Selection of activating mutations of c-fms in FDC-P1 cells.
Glover HR; Baker DA; Celetti A; Dibb NJ
Oncogene; 1995 Oct; 11(7):1347-56. PubMed ID: 7478556
[TBL] [Abstract][Full Text] [Related]
9. FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance.
Taylor JR; Brownlow N; Domin J; Dibb NJ
Oncogene; 2006 Jan; 25(1):147-51. PubMed ID: 16170366
[TBL] [Abstract][Full Text] [Related]
10. The antitumor activity of homoharringtonine against human mast cells harboring the KIT D816V mutation.
Jin Y; Lu Z; Cao K; Zhu Y; Chen Q; Zhu F; Qian C; Pan J
Mol Cancer Ther; 2010 Jan; 9(1):211-23. PubMed ID: 20053766
[TBL] [Abstract][Full Text] [Related]
11. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.
Shah NP; Lee FY; Luo R; Jiang Y; Donker M; Akin C
Blood; 2006 Jul; 108(1):286-91. PubMed ID: 16434489
[TBL] [Abstract][Full Text] [Related]
12. Ponatinib induces apoptosis in imatinib-resistant human mast cells by dephosphorylating mutant D816V KIT and silencing β-catenin signaling.
Jin B; Ding K; Pan J
Mol Cancer Ther; 2014 May; 13(5):1217-30. PubMed ID: 24552773
[TBL] [Abstract][Full Text] [Related]
13. Hotspot mutations in KIT receptor differentially modulate its allosterically coupled conformational dynamics: impact on activation and drug sensitivity.
Chauvot de Beauchêne I; Allain A; Panel N; Laine E; Trouvé A; Dubreuil P; Tchertanov L
PLoS Comput Biol; 2014 Jul; 10(7):e1003749. PubMed ID: 25079768
[TBL] [Abstract][Full Text] [Related]
14. The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders.
Roskoski R
Pharmacol Res; 2018 Jul; 133():35-52. PubMed ID: 29704617
[TBL] [Abstract][Full Text] [Related]
15. EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation.
Pan J; Quintás-Cardama A; Kantarjian HM; Akin C; Manshouri T; Lamb P; Cortes JE; Tefferi A; Giles FJ; Verstovsek S
Blood; 2007 Jan; 109(1):315-22. PubMed ID: 16912224
[TBL] [Abstract][Full Text] [Related]
16. Detailed conformational dynamics of juxtamembrane region and activation loop in c-Kit kinase activation process.
Zou J; Wang YD; Ma FX; Xiang ML; Shi B; Wei YQ; Yang SY
Proteins; 2008 Jul; 72(1):323-32. PubMed ID: 18214972
[TBL] [Abstract][Full Text] [Related]
17. Structural basis for the dual recognition of helical cytokines IL-34 and CSF-1 by CSF-1R.
Ma X; Lin WY; Chen Y; Stawicki S; Mukhyala K; Wu Y; Martin F; Bazan JF; Starovasnik MA
Structure; 2012 Apr; 20(4):676-87. PubMed ID: 22483114
[TBL] [Abstract][Full Text] [Related]
18. Autoinhibition of the kit receptor tyrosine kinase by the cytosolic juxtamembrane region.
Chan PM; Ilangumaran S; La Rose J; Chakrabartty A; Rottapel R
Mol Cell Biol; 2003 May; 23(9):3067-78. PubMed ID: 12697809
[TBL] [Abstract][Full Text] [Related]
19. Novel imatinib derivatives with altered specificity between Bcr-Abl and FMS, KIT, and PDGF receptors.
Skobridis K; Kinigopoulou M; Theodorou V; Giannousi E; Russell A; Chauhan R; Sala R; Brownlow N; Kiriakidis S; Domin J; Tzakos AG; Dibb NJ
ChemMedChem; 2010 Jan; 5(1):130-9. PubMed ID: 19950162
[TBL] [Abstract][Full Text] [Related]
20. A shift of dynamic equilibrium between the KIT active and inactive states causes drug resistance.
Srikakulam SK; Bastys T; Kalinina OV
Proteins; 2020 Nov; 88(11):1434-1446. PubMed ID: 32530065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
